Announcing IndieBio SF’s Next Wave – VC-Founder Meetings (June 17 to 21) Learn More

TippingPoint Biosciences

First ever therapeutics for cancers driven by aberrant chromatin networks


Laura Hsieh

Founder & CEO

Company details

Packaging of our DNA into chromatin is critical for dictating which parts of the genome can be transcribed and which cannot. TippingPoint Biosciences is the first company to tackle the core problem of targeting and drugging only the defectively packaged regions of the cancer genome, without affecting other correctly packaged regions. The TippingPoint platform leverages the latest advances in condensate biology and advanced screening tools to generate small molecule hits that can specifically modulate disease chromatin networks in a test tube, providing a new class of small molecules to treat disease. As many hard-to-treat diseases are a result of aberrant chromatin, TippingPoint’s platform will be expanded to create next-generation therapies across oncology and neurodegenerative diseases, starting with DIPG, a rare and lethal pediatric cancer.

Get In Touch with TippingPoint Biosciences

Please tell us a little bit about yourself and why you'd like to get connected. TippingPoint Biosciences + SOSV will follow up with you via email.


No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.